4D Molecular Therapeutics (NASDAQ:FDMT) Insider Scott Bizily Sells 1,635 Shares

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) insider Scott Bizily sold 1,635 shares of the firm’s stock in a transaction dated Thursday, August 13th. The shares were sold at an average price of $12.00, for a total value of $19,620.00. Following the sale, the insider owned 8,617 shares in the company, valued at $103,404. The trade was a 15.95% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Scott Bizily also recently made the following trade(s):

• On Monday, August 17th, Scott Bizily sold 1,635 shares of 4D Molecular Therapeutics stock. The stock was sold at an average price of $12.20, for a total value of $19,947.00.
• On Tuesday, June 23rd, Scott Bizily sold 9,810 shares of 4D Molecular Therapeutics stock. The shares were sold at an average price of $12.00, for a total value of $117,720.00.

4D Molecular Therapeutics Stock Performance

Shares of NASDAQ FDMT opened at $14.55 on Tuesday. The stock has a market cap of $760.67 million, a price-to-earnings ratio of -5.53 and a beta of 2.73. The company has a current ratio of 8.03, a quick ratio of 8.03 and a debt-to-equity ratio of 0.05. 4D Molecular Therapeutics, Inc. has a 1-year low of $5.97 and a 1-year high of $15.03. The stock’s 50-day moving average is $11.06 and its 200 day moving average is $9.93.

4D Molecular Therapeutics (NASDAQ:FDMT) last released its earnings results on Thursday, August 13th. The company reported ($1.04) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.02) by ($0.02). 4D Molecular Therapeutics had a negative return on equity of 41.33% and a negative net margin of 194.74%.The firm had revenue of $3.78 million during the quarter, compared to the consensus estimate of $3.62 million. On average, sell-side analysts anticipate that 4D Molecular Therapeutics, Inc. will post -3.88 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. Dynamic Technology Lab Private Ltd purchased a new position in shares of 4D Molecular Therapeutics in the first quarter worth $39,000. Wexford Capital LP purchased a new stake in 4D Molecular Therapeutics during the 3rd quarter valued at $41,000. AQR Capital Management LLC purchased a new stake in 4D Molecular Therapeutics during the 1st quarter valued at $46,000. Daiwa Securities Group Inc. grew its holdings in 4D Molecular Therapeutics by 3,362.0% in the 4th quarter. Daiwa Securities Group Inc. now owns 6,370 shares of the company’s stock worth $48,000 after acquiring an additional 6,186 shares during the last quarter. Finally, Rangeley Capital LLC bought a new stake in 4D Molecular Therapeutics in the 2nd quarter worth $48,000. Institutional investors own 99.27% of the company’s stock.

Wall Street Analyst Weigh In

FDMT has been the topic of several recent research reports. B. Riley Financial reaffirmed a “buy” rating on shares of 4D Molecular Therapeutics in a report on Monday. The Goldman Sachs Group reissued a “buy” rating and issued a $32.00 price target on shares of 4D Molecular Therapeutics in a research note on Thursday. Weiss Ratings restated a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a research report on Friday, July 17th. Wall Street Zen cut 4D Molecular Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Finally, Chardan Capital upgraded 4D Molecular Therapeutics to a “strong-buy” rating in a report on Tuesday, July 28th. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $29.62.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.